[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunic Inc (IMUX)

Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 204,315
  • Shares Outstanding, K 13,621
  • Annual Sales, $ 0 K
  • Annual Income, $ -97,170 K
  • EBIT $ -110 M
  • EBITDA $ -109 M
  • 60-Month Beta 1.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.37

Options Overview Details

View History
  • Implied Volatility 148.06% (+30.75%)
  • Historical Volatility 50.60%
  • IV Percentile 25%
  • IV Rank 11.72%
  • IV High 773.64% on 10/21/25
  • IV Low 65.03% on 10/20/25
  • Expected Move (DTE 31) 2.21 (14.59%)
  • Put/Call Vol Ratio 1.14
  • Today's Volume 15
  • Volume Avg (30-Day) 79
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 2,048
  • Open Int (30-Day) 7,543
  • Expected Range 12.94 to 17.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.24
  • Number of Estimates 6
  • High Estimate $-0.63
  • Low Estimate $-2.41
  • Prior Year $-2.00
  • Growth Rate Est. (year over year) +38.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.12 +7.29%
on 06/23/26
15.84 -4.36%
on 07/17/26
+0.95 (+6.69%)
since 06/18/26
3-Month
8.50 +78.23%
on 04/27/26
15.84 -4.36%
on 07/17/26
+6.14 (+68.17%)
since 04/21/26
52-Week
5.06 +199.29%
on 12/30/25
15.84 -4.36%
on 07/17/26
+5.83 (+62.62%)
since 07/21/25

Most Recent Stories

More News
Immunic to Participate in Investor Conferences in July

NEW YORK , July 9, 2026 /PRNewswire/ --  Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic...

IMUX : 15.15 (+1.00%)
Immunic to Participate in Investor, Industry and Scientific Conferences in June

NEW YORK , June 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic...

IMUX : 15.15 (+1.00%)
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis –

IMUX : 15.15 (+1.00%)
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus ® –

IMUX : 15.15 (+1.00%)
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization –

IMUX : 15.15 (+1.00%)
Immunic: Q1 Earnings Snapshot

Immunic: Q1 Earnings Snapshot

IMUX : 15.15 (+1.00%)
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer –

IMUX : 15.15 (+1.00%)
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer

– Proven Leader in Neurology Drug Development, Including for Several Approved Multiple Sclerosis Therapies –

IMUX : 15.15 (+1.00%)
Immunic, Inc. Announces 1-for-10 Reverse Stock Split

NEW YORK , April 23, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic...

IMUX : 15.15 (+1.00%)
Immunic to Participate in Scientific and Medical Conferences in April

NEW YORK , April 9, 2026 /PRNewswire/ -- Immunic , Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases,...

IMUX : 15.15 (+1.00%)

Business Summary

Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis....

See More

Key Turning Points

3rd Resistance Point 15.87
2nd Resistance Point 15.64
1st Resistance Point 15.39
Last Price 15.15
1st Support Level 14.91
2nd Support Level 14.68
3rd Support Level 14.43

See More

52-Week High 15.84
Last Price 15.15
Fibonacci 61.8% 11.72
Fibonacci 50% 10.45
Fibonacci 38.2% 9.18
52-Week Low 5.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.